retatrutide trial weight loss Early data for demonstrates exceptional results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading obesity medications currently under The numbers from Lilly's Phase

SGLT2 Inhibitors: Choosing the Right Agent, can further support your prescribing decisions

Liver enzymes (ALT, AST) often improve in people with fatty liver disease as weight loss reduces liver fat

We thank Joanna Loizou and Anna Schrempf for providing p53 mutant human TERT-immortalized retinal pigment epithelial 1 (RPE1) cells

What the research shows: A randomized, placebo-controlled, double-blind study published in Nutrition Research examined the effects of a patented saffron extract in 60 mildly overweight women over 8 weeks

CalogeroAEFioreMGiaconeFAltomareMAseroPLeddaCet al

One recent study in patients with psoriasis and psoriatic arthritis found that overweight individuals who combined a GLP-1 agonist with an anti-IL-17 medication experienced both weight loss and improved disease control compared to those using immunosuppressive therapy alone